Prolonged enoxaparin therapy compared with standard-of-care antithrombotic therapy in opiate-treated patients undergoing primary percutaneous coronary intervention

References

• Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ, et al. ESC/EACTS guidelines on myocardial revascularization. Eur Heart J 2019;40:87-165. Epub 2018/ 08/31.
   Google Scholar
• Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr., Ganiats TG, Holmes DR Jr., Jaffe AS, Jneid H, Kelly RF, Kontos MC, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol 2014;64:e139–228. doi:10.1016/j.jacc.2014.09.017.
   PubMed Web of Science ®Google Scholar
• Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018;39:119–177. Epub 2017/ 09/10. doi:10.1093/eurheartj/ehx393.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, Teng R, Antonino MJ, Patil SB, Karunakaran A, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009;120:2577–2585. Epub 2009/ 11/20. doi:10.1161/CIRCULATIONAHA.109.912550.
   PubMed Web of Science ®Google Scholar
• Brandt JT, Payne CD, Wiviott SD, Weerakkody G, Farid NA, Small DS, Jakubowski JA, Naganuma H, Winters KJ. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 2007;153:66 e69–16. doi:10.1016/j.ahj.2006.10.010.
   Web of Science ®Google Scholar
• Joshi RR, Hossain R, Morton AC, Ecob R, Judge HM, Wales C, Walker JV, Karunakaran A, Storey RF. Evolving pattern of platelet P2Y12 inhibition in patients with acute coronary syndromes. Platelets 2014;25:416–422. doi:10.3109/09537104.2013.836175.
   PubMed Web of Science ®Google Scholar
• Alexopoulos D, Xanthopoulou I, Gkizas V, Kassimis G, Theodoropoulos KC, Makris G, Koutsogiannis N, Damelou A, Tsigkas G, Davlouros P, et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv 2012;5:797–804. doi:10.1161/CIRCINTERVENTIONS.112.972323.
   PubMed Web of Science ®Google Scholar
• Kubica J, Adamski P, Ostrowska M, Sikora J, Kubica JM, Sroka WD, Stankowska K, Buszko K, Navarese EP, Jilma B, et al. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. Eur Heart J 2016;37:245–252. doi:10.1093/eurheartj/ehv547.
   PubMed Web of Science ®Google Scholar
• Parodi G, Bellandi B, Xanthopoulou I, Capranzano P, Capodanno D, Valenti R, Stavrou K, Migliorini A, Antoniucci D, Tamburino C, et al. Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention. Circ Cardiovasc Interv 2015;8. Epub 2015/ 01/02. doi:10.1161/CIRCINTERVENTIONS.114.001593.
   PubMedGoogle Scholar
• Gue YX, Spinthakis N, Farag M, Kubica J, Siller-Matula JM, Srinivasan M, Gorog DA. Impact of pre-admission morphine on re-infarction in patients with STEMI treated with PPCI: a meta-analysis. Clin Pharmacol Ther 2020. Epub 2020/ 01/29. doi:10.1002/cpt.1798.
   PubMed Web of Science ®Google Scholar
• Zwart B, Yazdani M, Ow KW, Richardson JD, Iqbal J, Gunn JP, Storey RF. Use of glycoprotein IIb/IIIa antagonists to prevent stent thrombosis in morphine-treated patients with ST-elevation myocardial infarction. Platelets 2020;31:174-178. Epub 2019/ 09/11.
   Web of Science ®Google Scholar
• Furtado RHM, Nicolau JC, Guo J, Im K, White JA, Sabatine MS, Newby LK, Giugliano RP. Morphine and cardiovascular outcomes among patients with non-ST-segment elevation acute coronary syndromes undergoing coronary angiography. J Am Coll Cardiol 2020;75:289–300. Epub 2020/ 01/25. doi:10.1016/j.jacc.2019.11.035.
   PubMed Web of Science ®Google Scholar
• Siller-Matula JM, Specht S, Kubica J, Alexopoulos D, De Caterina R, Hobl EL, Jilma B, Christ G, Lang IM. Abciximab as a bridging strategy to overcome morphine-prasugrel interaction in STEMI patients. Br J Clin Pharmacol 2016;82:1343–1350. Epub 2016/ 07/02. doi:10.1111/bcp.13053.
   PubMed Web of Science ®Google Scholar
• Franchi F, Rollini F, Rivas A, Wali M, Briceno M, Agarwal M, Shaikh Z, Nawaz A, Silva G, Been L, et al. Platelet inhibition with cangrelor and crushed ticagrelor in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation 2019;139:1661–1670. Epub 2019/ 01/12. doi:10.1161/CIRCULATIONAHA.118.038317.
   PubMed Web of Science ®Google Scholar
• Sumaya W, Parker WAE, Fretwell R, Hall IR, Barmby DS, Richardson JD, Iqbal J, Adam Z, Morgan KP, Gunn JP, et al. Pharmacodynamic effects of a 6-hour regimen of enoxaparin in patients undergoing primary percutaneous coronary intervention (PENNY PCI study). Thromb Haemost 2018;118:1250–1256. Epub 2018/ 06/07. doi:10.1055/s-0038-1657768.
   PubMed Web of Science ®Google Scholar
• Montalescot G, Zeymer U, Silvain J, Boulanger B, Cohen M, Goldstein P, Ecollan P, Combes X, Huber K, Pollack C Jr., et al. Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial. Lancet 2011;378:693–703. Epub 2011/ 08/23. doi:10.1016/S0140-6736(11)60876-3.
   PubMed Web of Science ®Google Scholar
• Petersen JL, Mahaffey KW, Hasselblad V, Antman EM, Cohen M, Goodman SG, Langer A, Blazing MA, Le-Moigne-Amrani A, de Lemos JA, et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview. JAMA 2004;292:89–96. Epub 2004/ 07/09. doi:10.1001/jama.292.1.89.
   PubMed Web of Science ®Google Scholar
• Sanchez-Pena P, Hulot JS, Urien S, Ankri A, Collet JP, Choussat R, Lechat P, Montalescot G. Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis. Br J Clin Pharmacol 2005;60:364–373. Epub 2005/ 09/29. doi:10.1111/j.1365-2125.2005.02452.x.
   PubMed Web of Science ®Google Scholar
• Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium. Circulation 2011;123:2736–2747. Epub 2011/ 06/15. doi:10.1161/CIRCULATIONAHA.110.009449.
   PubMed Web of Science ®Google Scholar
• Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115:2344–2351. Epub 2007/ 05/02. doi:10.1161/CIRCULATIONAHA.106.685313.
   PubMed Web of Science ®Google Scholar
• van ‘T Hof AW, Liem A, Suryapranata H, Hoorntje JC, de Boer MJ, Zijlstra F. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Zwolle Myocardial Infarction Study Group. Circulation 1998;97:2302–2306. Epub 1998/ 06/25. doi:10.1161/01.CIR.97.23.2302.
   PubMed Web of Science ®Google Scholar
• Fabris E, van ‘T Hof A, Hamm CW, Lapostolle F, Lassen JF, Goodman SG, Ten Berg JM, Bolognese L, Cequier A, Chettibi M, et al. Clinical impact and predictors of complete ST segment resolution after primary percutaneous coronary intervention: A subanalysis of the ATLANTIC Trial. Eur Heart J Acute Cardiovasc Care 2019;8:208–217. Epub 2017/ 08/26. doi:10.1177/2048872617727722.
   PubMed Web of Science ®Google Scholar
• Bruno R, Baille P, Retout S, Vivier N, Veyrat-Follet C, Sanderink GJ, Becker R, Antman EM. Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina and non-ST-segment elevation myocardial infarction. Br J Clin Pharmacol 2003;56:407–414. doi:10.1046/j.1365-2125.2003.01904.x.
   PubMed Web of Science ®Google Scholar
• Ubaid S, Ford TJ, Berry C, Murray HM, Wrigley B, Khan N, Thomas MR, Armesilla AL, Townend JN, Khogali SS, et al. Cangrelor versus ticagrelor in patients treated with primary percutaneous coronary intervention: impact on platelet activity, myocardial microvascular function and infarct size: a randomized controlled trial. Thromb Haemost 2019l; 119:1171-1181. Epub 2019/ 05/28.
   PubMed Web of Science ®Google Scholar
• Storey RF, Gurbel PA, Ten Berg J, Bernaud C, Dangas GD, Frenoux JM, Gorog DA, Hmissi A, Kunadian V, James SK, et al. Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes. Eur Heart J 2019. Epub 2020/01/30. doi:10.1093/eurheartj/ehz807.
   PubMed Web of Science ®Google Scholar
• Franchi F, Rollini F, Cho JR, Bhatti M, DeGroat C, Ferrante E, Dunn EC, Nanavati A, Carraway E, Suryadevara S, et al. Impact of escalating loading dose regimens of ticagrelor in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of a prospective randomized pharmacokinetic and pharmacodynamic investigation. JACC Cardiovasc Interv 2015;8:1457–1467. Epub 2015/ 09/26. doi:10.1016/j.jcin.2015.02.030.
   PubMed Web of Science ®Google Scholar
• Niezgoda P, Sikora J, Baranska M, Sikora A, Buszko K, Sieminska E, Marszall MP, Siller-Matula JM, Jilma B, Alexopoulos D, et al. Crushed sublingual versus oral ticagrelor administration strategies in patients with unstable angina. A pharmacokinetic/pharmacodynamic study. Thromb Haemost 2017;117:718–726. Epub 2017/ 02/17. doi:10.1160/TH16-08-0670.
   PubMed Web of Science ®Google Scholar
• Rollini F, Franchi F, Hu J, Kureti M, Aggarwal N, Durairaj A, Park Y, Seawell M, Cox-Alomar P, Zenni MM, et al. Crushed prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary intervention: the CRUSH study. J Am Coll Cardiol 2016;67:1994–2004. Epub 2016/ 03/26. doi:10.1016/j.jacc.2016.02.045.
   PubMed Web of Science ®Google Scholar
• Sikora J, Niezgoda P, Baranska M, Buszko K, Skibinska N, Sroka W, Pstragowski K, Siller-Matula J, Bernd J, Gorog D, et al. METoclopramide administration as a strategy to overcome MORPHine-ticagrelOr interaction in patients with unstable angina pectoris-the metamorphosis trial. Thromb Haemost 2018;118:2126–2133. Epub 2018/ 11/20. doi:10.1055/s-0038-1675605.
   PubMed Web of Science ®Google Scholar